Citations

Clear

51 citation(s) found for "Dubinsky, M".

S1160 Corticosteroid-Sparing Effect of Upadacitinib in Patients With Moderately-to-Severely Active Crohn’s Disease
Dubinsky, Marla C. , D’Haens, Geert , Lacerda, Ana P. , Dubcenco, Elena, Anyanwu, Samuel I., Garrison, Andrew, Dewit, Olivier , Juillerat, Pascal , Panaccione, Remo , Fujii, Toshimitsu , Anyanwu, Samuel, Doshi, Chirag, Liu, Jianzhong , Loftus, Edward V.

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S887-S888

10.14309/01.ajg.0000954280.83972.54 Get It

S1166 Time to Relapse During Upadacitinib Maintenance Therapy in Patients With Ulcerative Colitis Who Had a Clinical Response to Induction Therapy
Dubinsky, Marla C. , Kujawski, Michelle, Eccleston, Jason , Yao, Xuan , Axelrad, Jordan E. , Loftus, Edward V.

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S892-S893

10.14309/01.ajg.0000954304.38542.d7 Get It

S1120 Vedolizumab Is Effective for the Treatment of Chronic Inflammatory Conditions of the Pouch in a Prospective Multicenter Study
Raffals, Laura H., Qazi, Taha , Beniwal‐Patel, Poonam , Dubinsky, Marla C. , Chang, Shannon, Higgins, Peter , Barr, Jennifer I., Anderson, Chelsea , Long, Millie D. , Barnes, Edward L. , Kayal, Maia , Deepak, Parakkal , Cross, Raymond K. , Herfarth, Hans

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S853-S854

10.14309/01.ajg.0000954120.56351.1a Get It

S909 Efficacy of Upadacitinib in Patients With Crohn’s Disease Activity Index-Based Eligibility Criteria: Post Hoc Analysis of U-EXCEL, U-EXCEED, and U-ENDURE Phase 3 Trials
Lichtenstein, Gary R. , DuVall, Aaron, Chapman, J. Casey, Lacerda, Ana P. , Anyanwu, Samuel I., Garrison, Andrew, Dubinsky, Marla C. , Rubin, David T. , Loftus, Edward V. , Regueiro, Miguel , Anyanwu, Samuel, O’Brien, Daniel J. , Liu, Jianzhong

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S678-S679

10.14309/01.ajg.0000953276.85317.47 Get It

Dietary Patterns Are Not Associated With Disease Activity Among Patients With Inflammatory Conditions of the Pouch in a Prospective Cohort
Barnes, Edward L. , Beniwal‐Patel, Poonam , Deepak, Parakkal , Raffals, Laura H., Kayal, Maia , Dubinsky, Marla C. , Chang, Shannon, Higgins, Peter , Barr, Jennifer I, Anderson, Chelsea , Long, Millie D. , Herfarth, Hans , Herfarth, Hans H , Kayal, Maia , Deepak, Parakkal , Barnes, Edward L , Cross, Raymond K.

Mayo Clinic

Crohn's & Colitis 360 | July 19, 2023 | Volume: 5 | Issue: 3 | Pages: No page available

10.1093/crocol/otad039 | PMID 37519405 Get It

Abstract Background Evidence-based recommendations regarding the influence of diet on inflammatory conditions of the pouch after restorative proctocolectomy with ileal pouch–anal anastomosis (IPAA) are limited. Methods We analyzed dietary patterns at enrollment in a prospective registry of patients with 1 of 4 inflammatory conditions of the pouch (acute pouchitis, chronic antibiotic-dependent pouchitis, chronic antibiotic refractory pouchitis, and Crohn’s disease of the pouch). We analyzed dietary intake by disease activity at enrollment and then compared dietary patterns among patients who remained in remission throughout the 12-month follow-up to those patients who experienced a disease relapse. We also compared dietary patterns among patients with inflammatory conditions of the pouch to the United States Department of Agriculture (USDA) recommended daily goals. Results Among 308 patients, there were no differences in dietary patterns among patients with 1 of the 4 disease states at enrollment. Additionally, among the 102 patients in remission at baseline, there were no significant differences noted among patients who went on to experience a disease flare in the 12 months after enrollment compared to those patients who remained in remission. However, patients with inflammatory conditions of the pouch demonstrated decreased intake of several food groups and macronutrients including dairy, fruits, vegetables, whole grains, and fiber when compared to USDA recommendations. Conclusions In a prospective cohort, we demonstrated no impact of dietary patterns on disease activity. The relative deficiencies in several food groups and macronutrients among patients after IPAA indicate the potential role of targeted nutritional counseling in this population.
DOP40 Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn’s disease treated with upadacitinib
Dubinsky, M, D’Haens, Geert , Panaccione, Remo, FUJII, Teruko, Lacerda, Ana P. , Dubcenco, Elena, Anyanwu, S., Doshi, C, Garrison, A, Liu, J, Dewit, Olivier , Juillerat, Pascal , Mallick, M, Loftus, Edward V.

Mayo Clinic

Journal of Crohn's and Colitis | January 30, 2023 | Volume: 17 | Issue: Supplement_1 | Pages: i104-i106

10.1093/ecco-jcc/jjac190.0080 Get It

Abstract Background Corticosteroids (CS) may be used for induction of remission in Crohn’s disease (CD); however, side effects, toxicities, and low rates of mucosal healing may limit their long-term use. Safety and efficacy of upadacitinib (UPA), an oral selective Janus kinase inhibitor, were evaluated among patients with CD receiving UPA with CS at baseline in phase 3 clinical trials. Methods In 2 phase 3 studies (U-EXCEL, NCT03345849; U-EXCEED, NCT03345836), patients with moderate-to-severe CD were randomized to 12-week induction with UPA 45 mg once daily (QD) or placebo (PBO). Patients who achieved clinical response to UPA 45 mg were rerandomized in U-ENDURE (NCT03345823) to UPA 30 mg QD, UPA 15 mg QD, or PBO for a 52-week maintenance period. Patients taking CS at baseline or week 0 of maintenance (end of induction) were included. A CS taper began at induction week 4 and continued during maintenance. Endpoints included the proportion of patients who discontinued CS use (CS-free) at week 12 or for ≥ 90 days prior to week 52, and achieved clinical remission by stool frequency/abdominal pain score or by Crohn’s Disease Activity Index (CDAI), enhanced clinical response, decrease of at least 100 points in CDAI from baseline, endoscopic remission, and endoscopic response at week 12 and week 52. CS daily dose (in prednisone equivalent doses) was recorded. Safety was assessed through induction and maintenance. Results Of 1021 patients evaluated, 358 (35.1%) were taking CS at baseline (mean daily prednisone equivalent dose, 23.0 mg). Greater changes from baseline in mean CS daily dose were observed with UPA vs PBO at induction week 12 (−17.3 mg vs −10.7 mg); these changes were sustained at maintenance week 52 (UPA 30 mg, −16.4 mg; UPA 15 mg, −17.4 mg; PBO, −14.7 mg). The proportion of patients who achieved a ≥ 50% reduction in CS daily dose was higher with UPA vs PBO at induction week 12 among patients taking CS at baseline (72.6% vs 48.4%) and at week 52 among patients taking CS at baseline or week 0 of maintenance (UPA 30 mg, 49.2%; UPA 15 mg, 44.4%; PBO, 11.1%). A significantly higher proportion of patients taking UPA vs PBO were CS-free and achieved clinical remission, clinical response, endoscopic response, and endoscopic remission at week 12 (Fig 1A) and week 52 (Fig 1B). Rates of adverse events (AEs), serious AEs, and discontinuation were comparable between groups (Table 1). Serious infections, opportunistic infections, and herpes zoster events were numerically higher with UPA vs PBO (Table 1). Conclusion Patients with CD taking CS were able to taper and discontinue their CS regimen and experience clinical and endoscopic improvements with UPA treatment during the induction and maintenance periods.
S38 On-Body Injector Administration of Risankizumab for Treatment of Moderate-to-Severe Crohn’s Disease: Data From the Fortify Open-Label Longitudinal Real-Life Handling Substudy
Griffith, Jenny, Neimark, Ezequiel, Song, Alexandra , Wallace, Kori, Nannapaneni, Sujani, Zhou, Ji, Andresen, Rachel, Kligys, Kristina, Liao, Xiaomei, Dubinsky, Marla C. , Loftus, Edward V.

Mayo Clinic

American Journal of Gastroenterology | December 5, 2022 | Volume: 117 | Issue: 12S | Pages: S10-S10

10.14309/01.ajg.0000897660.07812.b5 Get It

Humoral Immune Response and Safety of SARS-CoV-2 Vaccination in Pediatric Inflammatory Bowel Disease
Kastl, Arthur , Weaver, Kimberly N. , Zhang, Xian , Strople, Jennifer A., Adler, Jeremy, Dubinsky, Marla C. , Bousvaros, Athos, Watkins, Runa , Dai, Xiangfeng , Chen, Wenli , Higgins, Peter , Bewtra, Meenakshi , Bellaguarda, Emanuelle, Chun, Kelly , Zikry, Michael, Fernando, Manory, Bastidas, Monique, Hernandez, Cristian, Craig, Riley, Boccieri, Margie E., Firestine, Anne, Long, Millie D. , Kastl, Arthur J , Adler, Jeremy, Cross, Raymond K. , Ungaro, Ryan C. , Farraye, Francis A. , Bastidas, Monique, Boccieri, Margie , Firestine, Ann M. , Kappelman, Michael D. , Adler, J

Mayo Clinic

American Journal of Gastroenterology | September 17, 2022 | Volume: 118 | Issue: 1 | Pages: 129-137

10.14309/ajg.0000000000002016 | PMID 36114773 Get It

INTRODUCTION: Children with inflammatory bowel disease (IBD) may respond differently to COVID-19 immunization as compared with healthy children or adults with IBD. Those younger than 12 years receive a lower vaccine dose than adults. We sought to describe the safety and humoral immune response to COVID-19 vaccine in children with IBD. METHODS: We recruited children with IBD, ages 5–17 years, who received ≥ 2 doses of the BNT162b2 vaccine by a direct-to-patient outreach and at select sites. Patient demographics, IBD characteristics, medication use, and vaccine adverse events were collected. A subset of participants had quantitative measurement of anti-receptor binding domain IgG antibodies after 2-part immunization. RESULTS: Our study population included 280 participants. Only 1 participant required an ED visit or hospitalization because of an adverse event. Of 99 participants who underwent anti-receptor binding domain IgG antibody measurement, 98 had a detectable antibody, with a mean antibody level of 43.0 μg/mL (SD 67) and a median of 22 μg/mL (interquartile range 12–38). In adjusted analyses, older age ( P = 0.028) and antitumor necrosis factor monotherapy compared with immunomodulators alone ( P = 0.005) were associated with a decreased antibody level. Antibody response in patients treated with antitumor necrosis factor combination vs monotherapy was numerically lower but not significant. DISCUSSION: Humoral immune response to COVID-19 immunization in children with IBD was robust, despite a high proportion of this pediatric cohort being treated with immunosuppressive agents. Severe vaccine-related AEs were rare. Overall, these findings provide a high level of reassurance that pediatric patients with IBD respond well and safely to SARS-CoV-2 vaccination.
Treatment Patterns and Standardized Outcome Assessments Among Patients With Inflammatory Conditions of the Pouch in a Prospective Multicenter Registry
Barnes, Edward L. , Deepak, Parakkal , Beniwal‐Patel, Poonam , Raffals, Laura H., Kayal, Maia , Dubinsky, Marla C. , Chang, Shannon, Higgins, Peter , Barr, Jennifer I, Galanko, Joseph A. , Jiang, Yue , Long, Millie D. , Dubinsky, Marla , Herfarth, Hans H , Kayal, Maia , Deepak, Parakkal , Jiang, Yue , Barnes, Edward L , Chang, Shannon, Cross, Raymond K. , Herfarth, Hans

Mayo Clinic

Crohn's & Colitis 360 | August 2, 2022 | Volume: 4 | Issue: 3 | Pages: No page available

10.1093/crocol/otac030 | PMID 36082341 Get It

Abstract Background Much of our understanding about the natural history of pouch-related disorders has been generated from selected populations. We designed a geographically diverse, prospective registry to study the disease course among patients with 1 of 4 inflammatory conditions of the pouch. The primary objectives in this study were to demonstrate the feasibility of a prospective pouch registry and to evaluate the predominant treatment patterns for pouch-related disorders. Methods We used standardized diagnostic criteria to prospectively enroll patients with acute pouchitis, chronic antibiotic-dependent pouchitis (CADP), chronic antibiotic refractory pouchitis (CARP), or Crohn’s disease (CD) of the pouch. We obtained detailed clinical and demographic data at the time of enrollment, along with patient-reported outcome (PRO) measures. Results We enrolled 318 patients (10% acute pouchitis, 27% CADP, 12% CARP, and 51% CD of the pouch). Among all patients, 55% were on a biologic or small molecule therapy. Patients with CD of the pouch were more likely to use several classes of therapy (P < .001). Among patients with active disease at the time of enrollment, 23% with CARP and 40% with CD of the pouch were in clinical remission at 6 months after enrollment. Conclusions In a population where most patients had refractory inflammatory conditions of the pouch, we established a framework to evaluate PROs and clinical effectiveness. This infrastructure will be valuable for long-term studies of real-world effectiveness for pouch-related disorders.
Low Rates of Breakthrough COVID-19 Infection After SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease
Weaver, Kimberly N. , Zhang, Xian , Dai, Xiangfeng , Chen, Wenli , Watkins, Runa , Adler, Jeremy, Dubinsky, Marla C. , Kastl, Arthur , Bousvaros, Athos, Strople, Jennifer , Higgins, Peter , Bewtra, Meenakshi , Bellaguarda, Emanuelle, Craig, Riley, Hernandez, Cristian, Boccieri, Margie , Firestine, Ann M. , Chun, Kelly , Long, Millie D. , Cross, Raymond , Adler, Jeremy, Cross, Raymond K. , Ungaro, Ryan C. , Farraye, Francis A. , Kappelman, Michael D. , Adler, J

Mayo Clinic

Inflammatory Bowel Diseases | July 13, 2022 | Volume: 29 | Issue: 3 | Pages: 483-486

10.1093/ibd/izac138 | PMID 35830416 Get It

Lay SummaryWe demonstrate low rates of breakthrough coronavirus disease 2019 (COVID-19) infection and mild course of illness following severe acute respiratory syndrome coronavirus 2 vaccination in a large cohort of inflammatory bowel disease patients. Residence in southern United States and lower median anti-receptor binding antibody level were associated with development of COVID-19.